SLC35A2 and gastric cancer: Summarily, SLC35A2 may be employed as a reliable prognostic marker for gastric cancer patients, with the potential to serve as an important metabolic regulator in cancer cells and immune cells, which is expected to become a new metabolic and immune target for cancer treatment.